Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference
DUBLIN, Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013. The webcast is scheduled to begin at 10:00 a.m. PST (6:00 p.m. GMT). Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals, will present an overview of the company and provide a business and financial update.
The webcast can be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. An archived version of the webcast will be available at the same location for at least one week following the presentation.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma. For further information, see www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals plc
More by this Source
Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015
22 Jul, 2015, 21:05 BST
Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8
01 Jul, 2015, 21:05 BST
Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or with Obstructive Sleep Apnea (OSA)
08 Jun, 2015, 14:05 BST
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382